Tools to define the melanoma-associated immunopeptidome

Immunology

Volumn 152, Issue 4, 2017, Pages 536-544

  Bräunlein, Eva ^a   Krackhardt, Angela M ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

immunogenicity; immunopeptidome; melanoma; T cells; tumor antigens; tumor rejection

Indexed keywords

IMMUNOPEPTIDOME; PEPTIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; TUMOR PROTEIN;

ANTIGEN DETECTION; CELL STRUCTURE; HUMAN; IMMUNE SYSTEM; IMMUNOPEPTIDOMICS; MASS SPECTROMETRY; MELANOMA; MELANOMA CELL; PEPTIDOMICS; PRIORITY JOURNAL; REVIEW; TARGET CELL; TUMOR IMMUNITY; ANIMAL; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; PROTEOMICS;

ANIMALS; ANTIGENS, NEOPLASM; HUMANS; IMMUNOTHERAPY; MELANOMA; NEOPLASM PROTEINS; PEPTIDES; PROTEOMICS;

EID: 85034062924     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12803     Document Type: Review

References (130)

1. Eggermont AM, Suciu S, Testori A, Santinami M, Kruit WH, Marsden J et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon α-2b versus observation in resected stage III melanoma. J Clin Oncol 2012; 30:3810–8.
2. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314:126–9.
3. Terando AM, Faries MB, Morton DL. Vaccine therapy for melanoma: current status and future directions. Vaccine 2007; 25(Suppl. 2):B4–16.
4. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011; 364:2119–27.
5. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114:535–46.
6. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015; 348:62–8.
7. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192:1027–34.
8. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271:1734–6.
9. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015; 27:450–61.
10. Balar AV, Weber JS. PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother 2017; 66:551–64.
11. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:23–34.
12. Zinkernagel RM, Doherty PC. MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv Immunol 1979; 27:51–177.
13. Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974; 248:701–2.
14. Townsend AR, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 1986; 44:959–68.
15. Vyas JM, Van der Veen AG, Ploegh HL. The known unknowns of antigen processing and presentation. Nat Rev Immunol 2008; 8:607–18.
16. Hedrick SM, Cohen DI, Nielsen EA, Davis MM. Isolation of cDNA clones encoding T cell-specific membrane-associated proteins. Nature 1984; 308:149–53.
17. Yanagi Y, Yoshikai Y, Leggett K, Clark SP, Aleksander I, Mak TW. A human T cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains. Nature 1984; 308:145–9.
18. Lanzavecchia A. Is the T-cell receptor involved in T-cell killing? Nature 1986; 319:778–80.
19. Garcia KC, Adams JJ, Feng D, Ely LK. The molecular basis of TCR germline bias for MHC is surprisingly simple. Nat Immunol 2009; 10:143–7.
20. Sharon E, Sibener LV, Battle A, Fraser HB, Garcia KC, Pritchard JK. Genetic variation in MHC proteins is associated with T cell receptor expression biases. Nat Genet 2016; 48:995–1002.
21. Klein L, Kyewski B, Allen PM, Hogquist KA. Positive and negative selection of the T cell repertoire: what thymocytes see (and don't see). Nat Rev Immunol 2014; 14:377–91.
22. Ehrlich P. Über den jetzigen Stand der Karzinomforschung. Beiträge zur experimentellen Pathologie und Chemotherapie. Leipzig, Akademische Verlagsgesellschaft 1909; 5:117–64.
23. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646–74.
24. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565–70.
25. Verdegaal EM, de Miranda NF, Visser M, Harryvan T, van Buuren MM, Andersen RS et al. Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature 2016; 536:91–5.
26. Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L et al. T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med 2016; 375:2255–62.
27. Reeves E, James E. Antigen processing and immune regulation in the response to tumours. Immunology 2017; 150:16–24.
28. Sadovnikova E, Stauss HJ. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. Proc Natl Acad Sci USA 1996; 93:13114–8.
29. Schuster IG, Busch DH, Eppinger E, Kremmer E, Milosevic S, Hennard C et al. Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies. Blood 2007; 110:2931–9.
30. Stanislawski T, Voss RH, Lotz C, Sadovnikova E, Willemsen RA, Kuball J et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2001; 2:962–70.
31. Sumner WC, Foraker AG. Spontaneous regression of human melanoma: clinical and experimental studies. Cancer 1960; 13:79–81.
32. Knuth A, Danowski B, Oettgen HF, Old LJ. T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc Natl Acad Sci USA 1984; 81:3511–5.
33. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988; 319:1676–80.
34. Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994; 180:35–42.
35. Storkus WJ, Zeh HJ III, Maeurer MJ, Salter RD, Lotze MT. Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J Immunol 1993; 151:3719–27.
36. Maczek C, Berger TG, Schuler-Thurner B, Schultz ES, Hamann A, Dunbar PR et al. Differences in phenotype and function between spontaneously occurring melan-A-, tyrosinase- and influenza matrix peptide-specific CTL in HLA-A*0201 melanoma patients. Int J Cancer 2005; 115:450–5.
37. Jacobs JF, Aarntzen EH, Sibelt LA, Blokx WA, Boullart AC, Gerritsen MJ et al. Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients. Cancer Immunol Immunother 2009; 58:145–51.
38. Boon T, Old LJ. Cancer tumor antigens. Curr Opin Immunol 1997; 9:681–3.
39. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009; 100:2014–21.
40. Lawson DH, Lee S, Zhao F, Tarhini AA, Margolin KA, Ernstoff MS et al. Randomized, placebo-controlled, phase III trial of yeast-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) versus peptide vaccination versus GM-CSF plus peptide vaccination versus placebo in patients with no evidence of disease after complete surgical resection of locally advanced and/or stage IV melanoma: a trial of the eastern cooperative oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697). J Clin Oncol 2015; 33:4066–76.
41. van Baren N, Bonnet MC, Dreno B, Khammari A, Dorval T, Piperno-Neumann S et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 2005; 23:9008–21.
42. Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol 2014; 11:509–24.
43. Andersen MH, Pedersen LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Can Res 2001; 61:869–72.
44. Leisegang M, Wilde S, Spranger S, Milosevic S, Frankenberger B, Uckert W et al. MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. J Clin Investig 2010; 120:3869–77.
45. Warren EH, Vigneron NJ, Gavin MA, Coulie PG, Stroobant V, Dalet A et al. An antigen produced by splicing of noncontiguous peptides in the reverse order. Science 2006; 313:1444–7.
46. Liepe J, Marino F, Sidney J, Jeko A, Bunting DE, Sette A et al. A large fraction of HLA class I ligands are proteasome-generated spliced peptides. Science 2016; 354:354–8.
47. Ebstein F, Textoris-Taube K, Keller C, Golnik R, Vigneron N, Van den Eynde BJ et al. Proteasomes generate spliced epitopes by two different mechanisms and as efficiently as non-spliced epitopes. Sci Rep 2016; 6:24032.
48. Vigneron N, Stroobant V, Chapiro J, Ooms A, Degiovanni G, Morel S et al. An antigenic peptide produced by peptide splicing in the proteasome. Science 2004; 304:587–90.
49. Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci USA 2005; 102:16013–8.
50. Fritsch EF, Rajasagi M, Ott PA, Brusic V, Hacohen N, Wu CJ. HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol Res 2014; 2:522–9.
51. Kracht MJ, van Lummel M, Nikolic T, Joosten AM, Laban S, van der Slik AR et al. Autoimmunity against a defective ribosomal insulin gene product in type 1 diabetes. Nat Med 2017; 23:501–7.
52. Ronsin C, Chung-Scott V, Poullion I, Aknouche N, Gaudin C, Triebel F. A non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ. J Immunol 1999; 163:483–90.
53. Laumont CM, Daouda T, Laverdure JP, Bonneil E, Caron-Lizotte O, Hardy MP et al. Global proteogenomic analysis of human MHC class I-associated peptides derived from non-canonical reading frames. Nat Commun 2016; 7:10238.
54. Aarnoudse CA, van den Doel PB, Heemskerk B, Schrier PI. Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int J Cancer 1999; 82:442–8.
55. Lupetti R, Pisarra P, Verrecchia A, Farina C, Nicolini G, Anichini A et al. Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage. J Exp Med 1998; 188:1005–16.
56. Turajlic S, Litchfield K, Xu H, Rosenthal R, McGranahan N, Reading JL et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol 2017; 18:1009–21.
57. Skipper JC, Hendrickson RC, Gulden PH, Brichard V, Van Pel A, Chen Y et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 1996; 183:527–34.
58. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371:2189–99.
59. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348:124–8.
60. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372:2509–20.
61. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV et al. Signatures of mutational processes in human cancer. Nature 2013; 500:415–21.
62. McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016; 351:1463–69.
63. McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 2017; 168:613–28.
64. Boon T, Kellermann O. Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line. Proc Natl Acad Sci USA 1977; 74:272–5.
65. Wolfel T, Van Pel A, De Plaen E, Lurquin C, Maryanski JL, Boon T. Immunogenic (tum-) variants obtained by mutagenesis of mouse mastocytoma P815. VIII. Detection of stable transfectants expressing a tum- antigen with a cytolytic T cell stimulation assay. Immunogenetics 1987; 26:178–87.
66. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269:1281–4.
67. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643–7.
68. Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg SA. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 1999; 284:1351–4.
69. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323–37.
70. Almeida LG, Sakabe NJ, deOliveira AR, Silva MC, Mundstein AS, Cohen T et al. CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res 2009; 37:D816–9.
71. Vita R, Overton JA, Greenbaum JA, Ponomarenko J, Clark JD, Cantrell JR et al. The immune epitope database (IEDB) 3.0. Nucleic Acids Res 2015; 43:D405–12.
72. Viatte S, Alves PM, Romero P. Reverse immunology approach for the identification of CD8 T-cell-defined antigens: advantages and hurdles. Immunol Cell Biol 2006; 84:318–30.
73. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R et al. Human neoplasms elicit multiple specific immune-responses in the autologous host. Proc Natl Acad Sci USA 1995; 92:11810–3.
74. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991; 351:290–6.
75. Rudensky A, Preston-Hurlburt P, Al-Ramadi BK, Rothbard J, Janeway CA Jr. Truncation variants of peptides isolated from MHC class II molecules suggest sequence motifs. Nature 1992; 359:429–31.
76. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50:213–9.
77. Andreatta M, Nielsen M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics 2016; 32:511–7.
78. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994; 152:163–75.
79. Hoof I, Peters B, Sidney J, Pedersen LE, Sette A, Lund O et al. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics 2009; 61:1–13.
80. Engels B, Engelhard VH, Sidney J, Sette A, Binder DC, Liu RB et al. Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell 2013; 23:516–26.
81. Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 1999; 17:51–88.
82. Jorgensen KW, Rasmussen M, Buus S, Nielsen M. NetMHCstab - predicting stability of peptide-MHC-I complexes; impacts for cytotoxic T lymphocyte epitope discovery. Immunology 2014; 141:18–26.
83. Soria-Guerra RE, Nieto-Gomez R, Govea-Alonso DO, Rosales-Mendoza S. An overview of bioinformatics tools for epitope prediction: implications on vaccine development. J Biomed Inform 2015; 53:405–14.
84. Abelin JG, Keskin DB, Sarkizova S, Hartigan CR, Zhang W, Sidney J et al. Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction. Immunity 2017; 46:315–26.
85. Antes I, Siu SW, Lengauer T. DynaPred: a structure and sequence based method for the prediction of MHC class I binding peptide sequences and conformations. Bioinformatics 2006; 22:e16–24.
86. Sorensen RB, Junker N, Kirkin A, Voigt H, Svane IM, Becker JC et al. The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines. Cancer Immunol Immunother 2009; 58:665–75.
87. Weinzierl AO, Lemmel C, Schoor O, Muller M, Kruger T, Wernet D et al. Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. Mol Cell Proteomics 2007; 6:102–13.
88. Bentzen AK, Hadrup SR. Evolution of MHC-based technologies used for detection of antigen-responsive T cells. Cancer Immunol Immunother 2017; 66:657–66.
89. Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M, Diekmann J et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 2015; 520:692–6.
90. Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med 2016; 22:433–8.
91. + T cells in human melanoma. Nat Med 2015; 21:81–5.
92. Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013; 19:747–52.
93. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 2017; 547:217–21.
94. Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Lower M et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 2017; 547:222–6.
95. Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992; 255:1261–3.
96. Rotzschke O, Falk K, Deres K, Schild H, Norda M, Metzger J et al. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 1990; 348:252–4.
97. Caron E, Kowalewski DJ, Chiek Koh C, Sturm T, Schuster H, Aebersold R. Analysis of major histocompatibility complex (MHC) immunopeptidomes using mass spectrometry. Mol Cell Proteomics 2015; 14:3105–17.
98. Gloger A, Ritz D, Fugmann T, Neri D. Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes. Cancer Immunol Immunother 2016; 65:1377–93.
99. Klar R, Schober S, Rami M, Mall S, Merl J, Hauck SM et al. Therapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands on myeloid leukemia cells by TCR-transgenic T cells. Leukemia 2014; 28:2355–66.
100. Berlin C, Kowalewski DJ, Schuster H, Mirza N, Walz S, Handel M et al. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy. Leukemia 2015; 29:647–59.
101. Walz S, Stickel JS, Kowalewski DJ, Schuster H, Weisel K, Backert L et al. The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy. Blood 2015; 126:1203–13.
102. Bassani-Sternberg M, Barnea E, Beer I, Avivi I, Katz T, Admon A. Soluble plasma HLA peptidome as a potential source for cancer biomarkers. Proc Natl Acad Sci USA 2010; 107:18769–76.
103. Ritz D, Gloger A, Neri D, Fugmann T. Purification of soluble HLA class I complexes from human serum or plasma deliver high quality immuno peptidomes required for biomarker discovery. Proteomics 2017; doi:10.1002/pmic.201600364.
104. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014; 515:572–6.
105. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014; 515:577–81.
106. Kalaora S, Barnea E, Merhavi-Shoham E, Qutob N, Teer JK, Shimony N et al. Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens. Oncotarget 2016; 7:5110–7.
107. Bassani-Sternberg M, Braunlein E, Klar R, Engleitner T, Sinitcyn P, Audehm S et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun 2016; 7:13404.
108. Khodadoust MS, Olsson N, Wagar LE, Haabeth OA, Chen B, Swaminathan K et al. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. Nature 2017; 543:723–7.
109. Bassani-Sternberg M, Gfeller D. Unsupervised HLA peptidome deconvolution improves ligand prediction accuracy and predicts cooperative effects in peptide–HLA interactions. J Immunol 2016; 197:2492–9.
110. Sofron A, Ritz D, Neri D, Fugmann T. High-resolution analysis of the murine MHC class II immunopeptidome. Eur J Immunol 2016; 46:319–28.
111. Pearson H, Daouda T, Granados DP, Durette C, Bonneil E, Courcelles M et al. MHC class I-associated peptides derive from selective regions of the human genome. J Clin Investig 2016; 126:4690–701.
112. Aebersold R, Mann M. Mass-spectrometric exploration of proteome structure and function. Nature 2016; 537:347–55.
113. Menschaert G, Vandekerckhove TT, Baggerman G, Schoofs L, Luyten W, Van Criekinge W. Peptidomics coming of age: a review of contributions from a bioinformatics angle. J Proteome Res 2010; 9:2051–61.
114. Deutsch EW, Overall CM, Van Eyk JE, Baker MS, Paik YK, Weintraub ST et al. Human proteome project mass spectrometry data interpretation guidelines 2.1. J Proteome Res 2016; 15:3961–70.
115. Olsen JV, Mann M. Status of large-scale analysis of post-translational modifications by mass spectrometry. Mol Cell Proteomics 2013; 12:3444–52.
116. Andersen R, Donia M, Ellebaek E, Borch TH, Kongsted P, Iversen TZ et al. Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen. Clin Cancer Res 2016; 22:3734–45.
117. Prickett TD, Crystal JS, Cohen CJ, Pasetto A, Parkhurst MR, Gartner JJ et al. Durable complete response from metastatic melanoma after transfer of autologous T cells recognizing 10 mutated tumor antigens. Cancer Immunol Res 2016; 4:669–78.
118. Anderson KG, Stromnes IM, Greenberg PD. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell 2017; 31:311–25.
119. Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015; 350:1079–84.
120. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015; 350:1084–9.
121. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994; 91:3515–9.
122. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994; 91:6458–62.
123. Wolfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Buschenfelde KH et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994; 24:759–64.
124. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94:1914–8.
125. Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E et al. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996; 183:1185–92.
126. Huang J, El-Gamil M, Dudley ME, Li YF, Rosenberg SA, Robbins PF. T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. J Immunol 2004; 172:6057–64.
127. + T cells. J Exp Med 1999; 189:1659–68.
128. Wolfel C, Drexler I, Van Pel A, Thres T, Leister N, Herr W et al. Transporter (TAP)- and proteasome-independent presentation of a melanoma-associated tyrosinase epitope. Int J Cancer 2000; 88:432–8.
129. Dalet A, Robbins PF, Stroobant V, Vigneron N, Li YF, El-Gamil M et al. An antigenic peptide produced by reverse splicing and double asparagine deamidation. Proc Natl Acad Sci USA 2011; 108:E323–31.
130. Ayyoub M, Stevanovic S, Sahin U, Guillaume P, Servis C, Rimoldi D et al. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J Immunol 2002; 168:1717–22.